These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15701432)

  • 41. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
    Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
    J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience.
    Kandus A; Grego K; Arnol M; Kovac D; Lindic J; Buturović J; Ponikvar R; Bren AF
    Transplant Proc; 2006 Nov; 38(9):2853-5. PubMed ID: 17112847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors.
    Gavela Martínez E; Sancho Calabuig A; Escudero Quesada V; Avila Bernabeu AI; Beltrán Catalán S; Morales García AI; Crespo Albiach JF; Pallardó Mateu LM
    Transplant Proc; 2008 Nov; 40(9):2900-2. PubMed ID: 19010141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Sequential protocols with thymoglobuline and delayed introduction of calcineurin: effects on renal function in renal transplant recipients with non immunological risk and low risk of delayed graft function].
    Ricard-Sutra E; Garrigue V; Bismuth J; Chong G; Argiles A; Mourad G
    Nephrologie; 2004; 25(4):127-32. PubMed ID: 15291140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.
    Grundy N; Simmonds J; Dawkins H; Rees P; Aurora P; Burch M
    J Heart Lung Transplant; 2009 Dec; 28(12):1279-84. PubMed ID: 19864164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
    Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
    Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Independent predictors of renal dysfunction after heart transplantation in patients with normal pretransplant renal function.
    Garrido IP; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Vázquez-Rey E; Pérez-Fernández R; García-Lara J; Cuenca-Castillo JJ; Castro-Beiras A
    J Heart Lung Transplant; 2005 Sep; 24(9):1226-30. PubMed ID: 16143237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis.
    Liu Y; Zhou P; Han M; Xue CB; Hu XP; Li C
    Transplant Proc; 2010 Jun; 42(5):1667-70. PubMed ID: 20620496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
    Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
    Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The safety and efficacy of basiliximab as induction agent in preventing early acute rejection in Chinese cardiac transplantation receipts].
    Huang J; Zheng Z; Hu SS; Song YH; Yang YJ; Zhu J; Liu P; Zhao H; Li LH; Liu MZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Dec; 34(12):1105-7. PubMed ID: 17274902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose basiliximab induction therapy in heart transplantation.
    Kittipibul V; Tantrachoti P; Ongcharit P; Ariyachaipanich A; Siwamogsatham S; Sritangsirikul S; Thammanatsakul K; Puwanant S
    Clin Transplant; 2017 Dec; 31(12):. PubMed ID: 28990220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: An analysis of the International Society for Heart and Lung Transplantation database.
    Butts RJ; Dipchand AI; Sutcliffe D; Bano M; Dimas V; Morrow R; Das B; Kirk R
    Pediatr Transplant; 2018 Jun; 22(4):e13190. PubMed ID: 29878688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction.
    Nampoory MR; Abdulhalim M; Johny KV; Al-Jawad Donia FA; Nair MP; Said T; Homoud H; Samhan M; Al-Mousawi M
    Transplant Proc; 2002 Nov; 34(7):2916-9. PubMed ID: 12431656
    [No Abstract]   [Full Text] [Related]  

  • 57. Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression.
    Boletis JN; Theodoropoulou H; Hiras T; Stamatiadis D; Darema M; Psimenou E; Stathakis C; Kostakis A
    Transplant Proc; 2001; 33(7-8):3184-6. PubMed ID: 11750366
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of induction strategy change on first-year rejection in pediatric heart transplantation at a single center-From postoperative basiliximab to either postoperative anti-thymocyte globulin or preoperative basiliximab.
    Sisson TM; Padilla LA; Hubbard M; Smith S; Pearce FB; Collins JL; Carlo WF
    Clin Transplant; 2021 Jun; 35(6):e14314. PubMed ID: 33838071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study.
    Angermann CE; Störk S; Costard-Jäckle A; Dengler TJ; Siebert U; Tenderich G; Rahmel A; Schwarz ER; Nägele H; Wagner FM; Haaff B; Pethig K
    Eur Heart J; 2004 Sep; 25(18):1626-34. PubMed ID: 15351162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.
    Langer RM; Hong DM; Katz SM; Van Buren CT
    Transplant Proc; 2002 Dec; 34(8):3162-4. PubMed ID: 12493406
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.